CN103966169A - Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof - Google Patents
Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof Download PDFInfo
- Publication number
- CN103966169A CN103966169A CN201310374517.2A CN201310374517A CN103966169A CN 103966169 A CN103966169 A CN 103966169A CN 201310374517 A CN201310374517 A CN 201310374517A CN 103966169 A CN103966169 A CN 103966169A
- Authority
- CN
- China
- Prior art keywords
- cell
- ctsc
- tongue squamous
- cell cancer
- squamous cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 210000004027 cell Anatomy 0.000 title abstract description 235
- 206010028980 Neoplasm Diseases 0.000 title abstract description 67
- 201000011510 cancer Diseases 0.000 title abstract description 16
- 210000004085 squamous epithelial cell Anatomy 0.000 title abstract 7
- 238000011160 research Methods 0.000 claims abstract description 24
- 238000002474 experimental method Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000001464 adherent effect Effects 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 48
- 235000015097 nutrients Nutrition 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 230000029087 digestion Effects 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 5
- 238000003119 immunoblot Methods 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 238000001262 western blot Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000000130 stem cell Anatomy 0.000 description 40
- 239000000243 solution Substances 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 34
- 206010062129 Tongue neoplasm Diseases 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 201000006134 tongue cancer Diseases 0.000 description 25
- 238000004321 preservation Methods 0.000 description 19
- 229960004756 ethanol Drugs 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 10
- 229920000936 Agarose Polymers 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 9
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 8
- 102000011782 Keratins Human genes 0.000 description 8
- 108010076876 Keratins Proteins 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000009871 tenuigenin Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 5
- -1 CK18 Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000035519 G0 Phase Effects 0.000 description 5
- 230000010190 G1 phase Effects 0.000 description 5
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940122618 Trypsin inhibitor Drugs 0.000 description 5
- 101710162629 Trypsin inhibitor Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 210000001047 desmosome Anatomy 0.000 description 5
- 230000004992 fission Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002753 trypsin inhibitor Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000321 buccal mucosa cell Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004691 chief cell of stomach Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003147 molecular marker Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960001957 stomatological preparations Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101150092476 ABCA1 gene Proteins 0.000 description 2
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000004160 Ammonium persulphate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 235000019395 ammonium persulphate Nutrition 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000003237 epithelioid cell Anatomy 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 210000003963 intermediate filament Anatomy 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 231100000693 bioaccumulation Toxicity 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003037 histogenic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000044172 human KRT18 Human genes 0.000 description 1
- 102000046414 human KRT19 Human genes 0.000 description 1
- 102000052309 human KRT8 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005165 macula densa Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940062190 pancreas extract Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000025358 tongue carcinoma Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an establishment method of a Chinese people tongue squamous epithelial cell cancer cell line and provides a material basis for research on characteristics and treatment drugs of people tongue squamous epithelial cell cancers. The establishment method comprises specific steps as follows: primary culture is performed on tongue squamous epithelial cell cancer cells with a tissue explant adherent method; subculture is performed when the cell density reaches about 80%; RT-PCR (reverse transcription-polymerase chain reaction) detection indicates that cells which are stable in subculture express people tongue squamous epithelial cell cancer cell indicative molecules CK8, 18 and 19; and western blot experiment detection indicates that adherent cells express people tongue squamous epithelial cell cancer cell indicative molecule CK8 and 18 proteins, so that the successful establishment of the Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 is proved at the molecular level.
Description
Technical field
The present invention relates to people's tongue squamous cell cancer cell technology field, particularly, relate to a kind of Chinese's tongue squamous cell cancer clone CTSC-1 and establishment method thereof.
Background technology
The morbidity of 1.1 tongue squamous cell cancers and prognosis
Tongue cancer is modal oral squamous cell carcinoma, often occurs in front 2/3 place of tongue.Tongue cancer is occurred frequently in South East Asia, and with India, for the highest, Annual occurence rate reaches 9.4/100 ten thousand.Recent study demonstration, in world wide, the total incidence of tongue cancer progressively improves, and has the trend of rejuvenation.Due to the histological characteristic of its happening part and the biological characteristics of tongue cancer, tongue cancer makes patient's tongue limitation of movement, and difficulty causes swallowing, speaks, takes food.In addition, tongue cancer easily shifts, and prognosis is poor.
The progress of 1.2 tumor stem cells
1.2.1 the proposition of tumor stem cell theory and development
Traditional concept thinks, tumour be a group by somatic mutation, obtain the cell composition of unlimited multiplication capacity, but the experiment of mouse tumorigenesis and body outer clone formation experimental result show, be not that all tumour cells can be bred.Illustrate that tumour is not the individuality of a homogeneous, it has heterogeneity, has different cell subsets in tissue.In tumor tissues, may some have the cell of stem cell characteristic, this cell type is called as tumor stem cell (cancer stem cell, CSC).
Tumor stem cell theory is proved in leukemia, Lapidot in 1994 etc. are utilized and in cell surface marker CD34+CD38-and mouse tumorigenesis model, are isolated people's acute myeloblastic leukemia (Acutemyeloid leukemia by FACS, AML) stem cell, subsequently, the discoveries such as Bonnet only have CD34+/CD38-leukemia cell can be in non-diabetic severe severe combined immunodeficiency (nonobese diabetic/severe combinedimmunodeflcient, NOD/SCID) Mice Body tumorigenesis.2003, Clarke etc. applied to tumor stem cell theory in solid tumor for the first time, and they have confirmed this viewpoint in mammary cancer, CD44+CD24-/low cell only need 100 just can tumorigenesis.Afterwards, research is found also can isolate tumor stem cell in the cancers such as cerebral tumor, liver cancer, lung cancer such as glioblastoma multiforme, has supported this theory.2006, AACR (American As sociation for Cancer Research) made definition to tumor stem cell: in tumour, have self-renewal capacity, and can produce the cell of heterogeneous tumour cell.It has three large characteristics: 1, differentiation capability: tumor stem cell is served as the role who forms and break up all types of tumour cells in tumour, in Tumor Growth, constantly supplements required all kinds of tumour cells.2, self-renewal capacity: generate a part with own identical, there is the cell of propagation, expansion and differentiation potential, thereby maintain the homeostasis of stem cell.3, Steady-State Control ability: the differentiation of adjusting and balance tumour, according to the stimulation of environment, tumour is made to regulation and control.
1.2.2 research and the application thereof of tumor stem cell in oral carcinoma
In the same cancer kitchen range of oral carcinoma tissue, include the cancer cells of different differentiation degrees, different steps.Studies confirm that, in incidence squamous cell cancer, exist a group to there is self, multi-lineage potential and have the cancer cells of tumorigenesis ability.Tumor stem cell is mostly in dormant state, insensitive to Radiotherapy chemotherapy, it is the root that after causing performing the operation, tumour easily recurs, resistance is strong, refractory is healed, the proposition of tumor stem cell theory can make the target for the treatment of from tumour global transfer to tumor stem cell, proposes the comprehensive therapy strategy combining for cancer cells and tumor stem cell.The research of tumor stem cell is also for the research of tumour has brought a new thinking.
The foundation of 1.3 clones
Setting up tumor cell line is that research tumour causes the important link in pass.Clone is widely used in each research field of biology.It refers to that directly separation and Culture goes out cell from the tissue of organism, for follow-up study provides a kind of method of stable cell lines.Clone is growth, metabolism, the modulating properties of research specific cells, cell and cell-cell interaction, and the interactions of cell and matrix etc. are research material effectively.The first strain continuous cell line of the mankind is the cervical cancer cell system (Hela) being set up by George Otto Gey laboratory nineteen fifty-one, the foundation of this strain clone is the milestone of human body cell vitro culture, Hela cell has advanced the process of many research fields such as cell, gene, virus, vaccine, has also deepened the understanding of people to tumour: find the various characteristics of tumour, reason and process, the screening cancer therapy drug etc. of research tumor development.Except the developing of the research characteristic of cell itself and cancer, be also applied to the research field of heredity, immunity, differentiation, growth.In addition, many enterprises can also utilize cell to produce the various factors, albumen etc. both at home and abroad.The widespread use of cell has promoted the flourish of cytobiology.
Former culture mainly contains mechanical process and enzyme digestion.Mechanical process is mainly to utilize physics to shear, and directly tissue is shredded, and then these is organized to the method for fritter adherent culture.Thereby enzyme digestion is the suitable enzymatic lysis tissue of application isolate unicellular, directly suspension or the method for adherent culture.Mainly contain for the enzyme digesting: trypsinase, collagenase, pronase, Unidasa etc.
The qualification of squamous cell cancer clone has the following aspects: 1, pathological section qualification: the World Health Organization (WHO, 2005) is divided into high, medium and low three grades according to cell and nuclear polymorphism, cell fission state, angling degree etc.Differentiated squama cancer is similar with normal tesselated epithelium, angling obviously, nuclear fission mutually less, cell and nucleus polymorphism not obvious; Middle differentiated squamous-cell carcinomas angling is more rare, nuclear fission mutually many, cell polymorphism is obvious; Low differentiated squamous-cell carcinomas has a large amount of nuclear fission phases, cell polymorphism is obvious, angling is very rare; 2, cellular form: be generally polygon Epithelial, nuclear-cytoplasmic ratio is high, the clear number of kernel is more, after cell arrangement is tight, is paving stone sample; 3, iuntercellular desmosome connects: on the film between flanking cell, have a border circular areas, responsible intercellular connection, communication, opposing external force are pullled, desmosome is more common in epithelium, the stratified squamous epithelium iuntercellular that skin, oral cavity, oesophagus etc. are located is more, can be destroyed by trypsinase, collagenase and Unidasa, under Electronic Speculum, mostly visible macula densa and Intermediate Filaments, be keratin filament in epithelial cell; 4, molecular marker: be mainly cytokeratin (cytokeratin, CK), be expressed in specifically epithelial cell, it is the Intermediate Filaments proteinoid that forms epithelial cell inner cell skeleton, have 20 kinds, CK1-9 is meta-alkalescence or neutral II type Keratin sulfate, and CK10-20 is the I type Keratin sulfate of slant acidity, these Keratin sulfate General Expressions are in specific organ or tissue, and CK8, CK18, CK19 are often expressed in simple epithelium.The above-mentioned biological characteristics that is characterized as the newly-established tongue squamous cell cancer clone of analysis of squamous cell cancer provides theoretical foundation.
The first strain tongue squamous cell cancer Establishment of Cell Line was in 1981, and by Japan Report, this strain clone fails to make mouse tumorigenesis.Then nineteen eighty-three has been set up a strain tongue cancer Tca8113 at China's Shanghai report, and 1995 have set up a strain tongue cancer cells PWH-S1 at China's Hong Kong report.Existing at Americantype culture collection(ATCC) in tongue cancer cells have 5 strains, be respectively SCC-15, SCC-4, SCC-25, SCC-9, CAL27, are all eighties in 20th century, rarely have afterwards report.
The biological characteristics of different Human Tongue Carcinoma Lines can there are differences, the method that this species diversity comes from patient itself and receives treatment.The degree of differentiation of some tongue cancer is low, and grade malignancy is high; The degree of differentiation of some tongue cancer is high, and grade malignancy is low.Some patient accepts chemotherapy in the preoperative, and therefore postoperative obtained cell has higher resistance.The existence of this species diversity just, makes our diversity to tongue cancer and complicacy have more understanding, and the tongue cancer cells there are differences just becomes research tongue cancer and occur effective external model of development.
Summary of the invention
For this reason, the invention provides a kind of Chinese's tongue squamous cell cancer clone CTSC-1 and establishment method thereof.
Technical scheme of the present invention is as follows: the establishment method of Chinese's tongue squamous cell cancer clone CTSC-1, comprises following concrete steps:
A) adopt tissue block adherent method to carry out the former culture of tongue squamous cell cancer cell;
B) cultivation of going down to posterity in the time that cell density reaches approximately 80%;
C) the stable cell that goes down to posterity is detected and shows cell expressing people tongue squamous cell cancer cell sign molecule CK8,18,19 through RT-PCR;
D) detect attached cell through immunoblot experiment and express people's tongue squamous cell cancer cell sign molecule CK8,18 albumen, prove successfully to set up Chinese's tongue squamous cell cancer clone CTSC-1 from molecular level thus, the CTSC-1 of acquisition is preserved in Chinese Typical Representative culture collection center; Address: Wuhan University of Wuhan, China city; Preserving number CCTCC NO:C2012176, preservation date is on November 14th, 2012.
The establishment method of described Chinese's tongue squamous cell cancer clone CTSC-1, the concrete grammar of steps A is:
1) the coated culture dish room temperature of type i collagen is static more than 1 hour, and 1 × PBS washes ware once, stand-by;
2) prepare nutrient solution, be put in 37 DEG C of thermostat water baths incubation 10 minutes;
3) in super clean bench, take out tongue squamous cell cancer tissue, in alcohol, sterilization is no more than 10 seconds, soaks in 1 × PBS, removes unwanted position, is put in nutrient solution;
4) tissue is cut into fine grained chippings, evenly divides and plant in culture dish, add appropriate nutrient solution, make to organize half to be dipped in nutrient solution;
5) be placed in 37 DEG C, 5%CO
2incubator in cultivate;
6) within second day, supplement appropriate nutrient solution to submergence tissue block slightly;
7) visual cell's growing state suitably changes liquid.
The establishment method of described Chinese's tongue squamous cell cancer clone CTSC-1, the concrete grammar of step B is:
1) abandon nutrient solution, wash once with 1 × PBS, add tryptic digestion;
2) add serum to stop digestion;
3) piping and druming cell, is placed in centrifuge tube, adds appropriate nutrient solution piping and druming;
4) centrifugal 1000rpm, 5 minutes;
5) abandon supernatant, add appropriate nutrient solution piping and druming loose;
6) cell suspension is added in new culture dish, obtain described Chinese's tongue squamous cell cancer clone CTSC-1.
The purposes of Chinese's tongue squamous cell cancer clone CTSC-1 in the medicine of research treatment people tongue squamous cell cancer.
The purposes of described Chinese's tongue squamous cell cancer clone CTSC-1 in the medicine for the treatment of people tongue squamous cell cancer.
Described Chinese's tongue squamous cell cancer clone CTSC-1 at Chinese Typical Representative culture collection center (Wuhan University's preservation center) carry out preservation.
Beneficial effect of the present invention is: the present invention has set up Chinese's tongue squamous cell cancer clone CTSC-1, and realized the enrichment of tumor stem cell by this clone, for characteristic and the medicine thereof of research people tongue squamous cell cancer provide basic substance.
Brief description of the drawings
Fig. 1, cell derived patient tissue section H & E dyeing, the cellular form of light Microscopic observation primary cell and CTSC-1 continuous cell line.
Under Fig. 2, transmission electron microscope, observe the ultrastructure figure of CTSC-1 cell.
Fig. 3, sepharose detect the CK8,18 of normal buccal mucosa cell, CAL27 tongue cancer cells, CTSC-1 cell, the expression of 19 mRNA;
Fig. 4, Western western blotting method detect the CK8,18 and the protein expression situation of E-cadherin of CAL27 tongue cancer cells, CTSC-1 cell.
Fig. 5, CTSC-1 cell chromosome show;
Fig. 6, random select to have calculated after 100 finely dispersed CTSC-1 cell chromosomes add up acquired results with SSCP;
The cell growth curve of Fig. 7, CTSC-1 cell;
The clone of Fig. 8, CTSC-1 cell forms;
Fig. 9, CTSC-1 cell mouse transplanted tumor tissue slice H & E dyeing;
Figure 10, immunofluorescence detect CTSC-1 clone to CD133, Sox2, Nanog, Oct4, SSEA-1, SSEA-4, TRA-1-60, the expression of TRA-1-81;
Figure 11, serum-free suspension culture enrichment CTSC-1 clone tumor stem cell and morphological observation thereof;
Figure 12, H & E dyeing CTSC-1 sacculus cell;
Figure 13, CTSC-1 sacculus cell and the expression of attached cell to CK8, CK18, CK19;
Figure 14, CTSC-1 attached cell and the clone of sacculus cell in BME form statistics;
Figure 15, flow cytometer detect the contrast of the stem cell molecular marker expression of CTSC-1 sacculus cell and attached cell;
Figure 16, detect the differentiation capability result of CTSC-1 sacculus cell by the method for fatty inducing culture.
Embodiment
Below with reference to specific embodiment, the establishment method of Chinese's tongue cancer cells CTSC-1 of the present invention is further illustrated.
One, foundation and the CHARACTERISTICS IDENTIFICATION of tongue squamous cell cancer clone CTSC-1
Material explanation:
1 clinical samples
This is tested oral cavity tissue used and all takes from Zhongshan University's attached brilliance stomatological hospital excision sample.
2 clones
This tests tongue squamous cell cancer CAL27 cell strain used purchased from ATCC
3 key instruments
4, main agents
5 main solution and formulas
5.1 cell cultures
1) 10 × PBS Buffer:NaCl80g, KCl2g, Na
2hPO
411.55g, KH
2pO
42g, adds the ultrapure water of about 800ml, and the abundant stirring and dissolving of magnetic stirring apparatus regulates pH value to 7.4, is settled to 1L, after autoclave sterilization, and room temperature preservation.
2) foetal calf serum (FBS): purchased from Hyclone company, 4 DEG C of preservations, and substratum is made into suitable proportion.
3) 10 × Trypsin-EDTA (TE): take 1.25g trypsin, 1.00g EDTA is dissolved in 1 × PBS of 250ml, filtration sterilization ,-20 DEG C of preservations.Before using, be diluted to proper concn peptic cell with 1 × PBS buffer.
4) DMEM/F12(DF) substratum: be dissolved in the ultrapure water of 1L, regulate pH value to 7.2, utilize peristaltic pump and 0.22 μ m membrane filtration degerming.4 DEG C of preservations.2 × DF component doubles, and the water yield is constant.DF(-) represent not add Ampicillin and Kanamycin.
5) mouse tail NTx: when former culture, be diluted to 1% concentration with 1 × PBS, at the bottom of adding 1.5mL to cover ware on the ware of each six centimetres, room temperature is coated more than 1 hour.
6) soft agar: soft agar adds ultrapure water, autoclave sterilization is made into 0.66% and 1.33%.
7) colchicine: 40 μ g/mL mother liquors, final working concentration is 0.2 μ g/mL.
8) the primary nutrient solution of tongue cancer: DF+10%FBS.
5.2 nucleic acid electrophoresis
1) 50 × TAE electrophoresis Buffer(pH8.5): in the vial of 1L, add 242g Tris, 18.6g Na
2eDTA2H
2o, then adds the secondary water of about 800ml, fully stirring and dissolving, then add the acetic acid of 57.1ml, and fully stir, add secondary water and be settled to 1L, room temperature preservation.When use, dilute with 1:50.
2) ethidium bromide (EB): storage liquid concentration is 10mg/ml, working concentration is 0.5 μ g/ml.
3) 1% Normal Agarose Gel: take 1g agarose (agarose), add 100ml1 × TAE buffer, heated and boiled to agarose dissolves completely, be chilled to 50 DEG C of left and right, add 5 μ l EB storage liquid, making final concentration is 0.5 μ g/ml, records gel flat board after shaking up.
5.3Western immunoblotting
1) protein lysate (RIPA):
| Component | Mother liquor | 50ml system |
| 50mM Tris pH8.0 | 1M Tris pH8.0 | 2.5ml |
| 150mM NaCl | 5M NaCl | 1.5ml |
| 1mM EDTA | 0.5M EDTA | 0.1ml |
| 1%Triton x-100 | Triton x-100 | 0.5ml |
| 0.1%SDS | 10%SDS | 0.5ml |
| 0.25%Sodium deoxycholate | Sodium deoxycholate | 0.125g |
| dd water | Fill up to500ml | 44.9ml |
2) proteinase inhibitor: EDTA-free Protease Inhibitor Cocktail tablet (Roche, Cat.No.04693159001); In cocktail, include Pancreas-extract, Thermolysin (Metalloprotease), Chymotrypsin, Trypsin, the proteinase inhibitor such as Papain.A slice tablet adds 1ml1 × PBS and is made into 10 × cocktail storage liquid, when use, be diluted to 1 ×.
3) protein quantification: carry out according to GE2-D Quant Kit specification sheets.
4) 1M Tris-HCl (pH6.8): weigh 121.1g Tris and be placed in 1L bottle, add the secondary water of about 800ml, fully stirring and dissolving, with dissolved salt acid for adjusting pH value to 6.8, is settled to 1L by solution, after autoclave sterilization, room temperature preservation.
5) 1.5M Tris-HCl (pH8.8): weigh 181.7g Tris and be placed in 1L bottle, add the secondary water of about 800ml, fully stirring and dissolving, with dissolved salt acid for adjusting pH value to 8.8, is settled to 1L by solution.After autoclave sterilization, room temperature preservation.
6) 10% (W/V) ammonium persulphate claims 1.0g ammonium persulphate, adds 10ml secondary water fully to dissolve, 4 DEG C of temporary transient preservations.Or be distributed into 100 μ l aliquots, seal-20 DEG C of preservations.
7) 5 × Tris-Glycine Buffer (SDS-PAGE electrophoretic buffer) takes 15.1g Tris, 94g glycine, and 5.0g SDS, adds secondary water and is settled to 1L, room temperature preservation.When use, be diluted to 1 × damping fluid with secondary water.
8) 5 × SDS-PAGE Loading Buffer: the 1M Tris-HCl (pH6.8) that adds 1.25ml in the plastic centrifuge tube of 50ml, 0.5g SDS, 25mg tetrabromophenol sulfonphthalein, 2.5ml glycerine, then add secondary water and be settled to 50ml, a little after heat of solution, after aliquot (1ml/ pipe) packing, room temperature preservation.Before using, every 1ml LoadingBuffer adds the 1M DTT of 50 μ l2-mercaptoethanols or 0.25ml, fully mixes room temperature preservation.
9) 5% concentrated glue
10) 10% separation gel
11) transferring film liquid: 2.9g Glycine, 5.8g Tris, 0.37g SDS, the methyl alcohol of 200ml, is settled to 1L, room temperature preservation with secondary water.
12) 1 × TBST buffer:8.8g NaCl, the 1M Tris-HCl (pH8.0) of 20ml, adds the secondary water of about 800ml, and fully stirring and dissolving is settled to 1L with secondary water, fully mixes room temperature preservation after finally adding 1.0ml Tween20.
13) confining liquid: take 0.5g skim-milk and add in 10ml TBST buffer, fully mix dissolving, now with the current.
14) ECL luminescent solution: pierce ECL enhance chemiluminescent westhern blottingsubstrate, purchased from Thermo, before using, 1:1 mixes two kinds of liquid, now with the current.
5.4 histological chemistry
1) 10% formalin solution: 50mL formaldehyde solution (37%-40%) is added in 450mL1 × PBS, room temperature preservation.
2) 4% paraformaldehyde (4%PFA): the paraformaldehyde of 20g is poured in 1 × PBS of 400mL, 65 DEG C of dissolvings, when dissolving, shook up every 10-20 minute, be bordering on while dissolving completely, add the 1M NaOH of 40 μ l, 1 × PBS is settled to 500mL, after mixing, is cooled to room temperature, 4 DEG C of preservations.
5.5 antibody
5.6 primer
Human keratin 8 （CK8）
Forward TTC CTG GAG CAG CAG AAC AA
Reverse GAG GAC AAA TTC GTT CTC CAT
Human keratin 18 （CK18）
Forward TCA GCA GAT TGA GGA GAG CA
Reverse TCT GAC TCA AGG TGC AGC AG
Human keratin 19 （CK19）
Forward ATT CTT GGT GCC ACC ATT GA
Reverse TCC TCA TGG TTC TTC TTC AGG
6 methods and result:
Foundation and the morphological observation of 6.1 tongue squamous cell cancer clone CTSC-1
6.1.1 the former culture of cell and the cultivation of going down to posterity
Adopt tissue block adherent method to carry out the former culture of tongue squamous cell cancer cell:
1) the coated culture dish room temperature of type i collagen is static more than 1 hour, and 1 × PBS washes ware once, stand-by;
2) prepare nutrient solution, be put in 37 DEG C of thermostat water baths incubation 10 minutes;
3) in super clean bench, take out tissue (Zhongshan University's attached brilliance stomatological hospital excision sample), in alcohol, sterilization is no more than 10 seconds, soaks in 1 × PBS, removes unwanted position, is put in nutrient solution;
4) tissue is cut into fine grained chippings, evenly divides and plant in culture dish, add appropriate nutrient solution, make to organize half to be dipped in nutrient solution;
5) be placed in 37 DEG C, 5%CO
2incubator in cultivate;
6) within second day, supplement appropriate nutrient solution to submergence tissue block slightly;
7) visual cell's growing state suitably changes liquid.
In the time that reaching approximately 80%, cell density goes down to posterity:
1) abandon nutrient solution, wash once with 1 × PBS, add trysinization;
2) add serum to stop digestion;
3) piping and druming cell, is placed in centrifuge tube, adds appropriate nutrient solution piping and druming;
4) centrifugal 1000rpm, 5 minutes;
5) abandon supernatant, add appropriate nutrient solution piping and druming loose;
6) cell suspension is added in new culture dish.
Interpretation of result:
Just there is epithelioid cell to climb out of and form a circle cellular layer from tissue block by after above-mentioned primary culture method the 5th day, but poor growth always afterwards, and follow more fibroblastic growth.This research is taked gradient digestion and is scraped eliminating method except inoblast, until just go down to posterity for the first time after 3 months, cell one is the growth of clone's property, and has the phenomenon of tired layer growth.After living through and going down to posterity for 3 times, fibroblastic ratio reduces gradually, and epithelial cell proliferation is accelerated, and becomes pure epithelioid clone, called after CTSC-1 cell.So far, CTSC-1 cell has gone down to posterity more than 50 times, and cell state is stable.
Under light microscopic, the form of CTSC-1 passage cell as shown in Figure 1.Light Microscopic observation, CTSC-1 passage cell is typical Epithelial form, flat, polygon, cell presents paving stone shape after covering with culture dish.CTSC-1 passage cell and iuntercellular contact closer, in the form of sheets growth.More visible round cells under mirror, for entering division cells or senile cell, nuclear-cytoplasmic ratio is high, and kernel is clear, and quantity differs, and can reach at most 5-6.
6.1.2 fixing, the dehydration of oral cavity tissue, embedding, H & E dyeing procedure
1) 10% formalin or 4%PFA fixing port cavity tissue spend the night (will carry out embedding in one week);
2) on automatic dehydration instrument, dewater: 70% ethanol 2 hours, 80% ethanol 2 hours, 95% ethanol 30 minutes, 95% ethanol 30 minutes, dehydrated alcohol 30 minutes, dehydrated alcohol 2 hours, dehydrated alcohol+TO(1:1) 30 minutes, TO30 minute, TO2 hour, TO+ paraffin (1:1) 30 minutes, paraffin 3 hours, paraffin 2 hours.Totally 12 barrels, 16 hours;
3) on embedding machine, carry out embedding with paraffin, on slicing machine, cut into slices;
4) 60 DEG C, tissue is de-cured, dimethylbenzene 5 minutes, and two add benzene 5 minutes, dehydrated alcohol 1 minute, 90% ethanol 1 minute, 80% ethanol 1 minute, 70% ethanol 1 minute, distillation washing 4 minutes;
5) Hematorylin liquid dyeing 1-2 minute, tap water rinses 10 minutes, water-soluble Yihong dyeing 2-3 minute;
6) dehydration, transparent and mounting: section is added to 70% ethanol 30 seconds, 80% ethanol 30 seconds, 90% ethanol 1 minute, dehydrated alcohol 1 minute, dimethylbenzene 5 minutes, finally uses resinene mounting.
Under light microscopic, the form of CTSC-1 patient tissue cell as shown in Figure 1, cut into slices by oral cavity tissue patient tissue, be visible as squamous cell cancer, cell is the polygon differing in size, and has polymorphism, be arranged in nido, have matrix to hold around, nuclear fission is many mutually, and nuclear-cytoplasmic ratio is high, multinuclear benevolence or lobulated, there is keratin pearl in the patient tissue visible tumor center of cutting into slices, tumor invasion muscle layer, visible lymphocytic infiltration in tissue.
6.1.3CTSC-1 cell ultrastructure
Under transmission electron microscope, observe the Ulntrastructure of CTSC-1 cell as shown in Figure 2, visible cell has first antenna shape projection, can be observed golgi body, rrna, endoplasmic reticulum distribution in tenuigenin, also has a small amount of cavity, and nucleus is irregular, has 1-2 kernel obvious.Cell is not observed obvious desmosome with intercellular connection, iuntercellular is connected with tight section (shown in Fig. 2 arrow), but observe and in tenuigenin, arrange short compared with bibliographical information of fibril closely, may be that cancer cells can not form typical desmosome under culture condition in vitro, form the connection that is similar to desmosome.
6.1.4CTSC-1 the qualification of the significant molecule of cell
6.1.4.1 the extraction of normal buccal mucosa cell, CAL27 tongue cancer cells, CTSC-1 attached cell RNA (pressing the operation of Invitrogen Trizol test kit specification sheets)
1) cell in vegetative period of taking the logarithm, abandons nutrient solution, adds the cell concentration of 1ml Trizol(6cm ware more suitable in culture dish), blow and beat to lysis completely with pipettor, liquid is drawn to 1.5ml without in enzyme centrifuge tube;
2) room temperature is placed and within 5 minutes, is made nucleic acid-protein mixture separate completely, and 4 DEG C, centrifugal 10 minutes of 12000xg, gets supernatant;
3) every use 1ml Trizol adds chloroform 0.2ml, violent jolting 15s, and room temperature leaves standstill 3min and makes it layering, and 4 DEG C, centrifugal 15 minutes of 12000xg;
4)≤50% upper strata water is carefully transferred to another 1.5ml without in the clean centrifuge tube of enzyme;
5) every use 1ml Trizol adds 0.5ml Virahol, mixes gently, and room temperature leaves standstill 10 minutes, and 4 DEG C, centrifugal 10 minutes of 12000xg;
6) abandon supernatant, add without enzyme 75% ethanol 1ml along wall, mix gently;
7) 4 DEG C, centrifugal 5 minutes of 7500xg, abandons supernatant, and 1.5ml centrifuge tube is inverted, with the micropipet of the 100 μ l remaining ethanol that exhausts, dry, precipitation be dissolved in 20～40 μ l without in RNase water;
8) get 2 μ l, with ultraviolet spectrophotometer (Nanodrop) mensuration A260nm and A280nm, RNA concentration (μ g/ml)=A260nm × 40 × extension rate; Purity, reaches 1.8-2.0 and can be used for experiment than value representation with A260/A280, and-80 DEG C save backup.
6.1.4.1.2 extract oral cavity tissue RNA
1) claim oral cavity tissue 50-100mg to 1.5ml without in enzyme centrifuge tube, add 1mlTrizol, homogenizer is homogenate on ice; Or add again Trizol cracking with liquid nitrogen grinding is broken;
Subsequent step is with 2 of 6.1.4.1)-8).
6.1.4.1.3RT-PCR reverse transcription reaction (pressing the operation of TOYOBO ReverTra Ace-α-test kit specification sheets)
1) in PCR reaction tubes, be sequentially added into:
Total RNA 1 μ l (600ng)
10pmol/L Oigo(dT)5μl
RNase Free H
2O6μl
2) ice bath 1min after 65 DEG C of effect 5min, puts on ice and adds:
3) PCR instrument is set, 42 DEG C, 60min, 99 DEG C, 5min, 4 DEG C, hold, put-20 DEG C and save backup.
6.1.4.1.4PCR(press the operation of TOYOBO KOD-Plus-test kit specification sheets)
1) in PCR pipe, be sequentially added into:
2) PCR instrument is set, different primers is by characteristic settings such as various annealing temperatures, and PCR product first detects with agarose gel electrophoresis.
Sepharose detects the CK8,18 of normal buccal mucosa cell, CAL27 tongue cancer cells, CTSC-1 cell, the expression of 19 mRNA, and result as shown in Figure 3.
6.1.4.1.5Western immunoblotting detects CAL27 tongue cancer cells, the CK8 of CTSC-1 cell, 18 protein expression situation.
Protein extracting method is as follows: add 5 times of cell volume protein lysates (RAPI) by cell volume, leave standstill cracking 60 minutes, ultrasonic disruption 10 minutes on ice; 4 DEG C, centrifugal 8 minutes of 12000xg; Supernatant is shifted and enters 1.5mL centrifuge tube without enzyme, add 10 × proteinase inhibitor to 1 × ,-80 DEG C save backup; By conventional Western western blotting method detection CAL27 tongue cancer cells, the CK8 of CTSC-1 cell, 18 protein expression situation.Result as shown in Figure 4.
Result shows, normal buccal mucosa epithelial cell, CAL27 tongue cancer cells, these three kinds of cells of CTSC-1 cell are all expressed CK8,18,19 mRNA, expression amount no significant difference.Because normal buccal mucosa epithelial cell is less, fail to propose albumen, therefore only detected CAL27 tongue cancer cells, the CK8 of CTSC-1 cell, 18 protein expression situation, result shows that the two all expresses, and expression amount is basically identical.This result has confirmed that from molecular level CTSC-1 cell is typical squamous cell.
6.1.5CTSC-1 DNA fingerprint qualification
6.1.5.1 STR (STR) is analyzed: STR (STR) is extensively to exist the strand of dna connection in genome to read sequence again, is made up of the core sequence of 2-6bp, conventionally repeats 15-30 time.STR sequence in organism genome is consistent and can entails filial generation, therefore can experimental results show that whether this research cultured cells is originated by its patient with STR.Oral cavity tissue is got to a fritter and the 8th generation of CTSC-1() cell of whole ware delivers to Zhongshan University's verification centre of forensic medicine and carries out Analysis and Identification.Result is as shown in table 1.
Table 1CTSC-1 cell and oral cavity tissue STR result
* light grey lattice represent the vicissitudinous gene of number
This experimental analysis has detected 25 sites, comprises an individual character chromosomal foci and 24 non-sex chromosome sites.CTSC-1 is at D16S539, Penta-D, and on FGA site, cell is compared with tissue, has lacked a kind of tumor-necrosis factor glycoproteins, and all the other are coupling completely all.
6.1.5.2, the aobvious band of Chromosome G is analyzed: process after 2 hours through colchicine (0.2 μ g/mL) in the CTSC-1 of logarithmic phase cell, peptic cell, after 1XPBS is resuspended, deliver to Zhongshan University's genetic research center and carry out film-making, the aobvious band of G is analyzed karyomit(e) situation, fetch again, after 100 finely dispersed CTSC-1 cell chromosomes of random selection calculating, add up acquired results with SSCP.Shown in result Fig. 5.
6.1.5.3, chromosome karyotype analysis:
1) change to the nutrient solution containing colchicine (0.2 μ g/mL) in logarithmic phase CTSC-1, cultivate 2 hours;
2) discard supernatant, 1 × PBS washes ware once, discards 1 × PBS, trypsin digestion and cell;
3) after FBS stops digestion, centrifugal 5 minutes of 1000rpm, removes supernatant;
4) add the KCL solution (0.075M) of 37 DEG C of preheatings to process 30 minutes (different cell asynchronism(-nization));
5) add 1mL stationary liquid (methyl alcohol: acetic acid=3:1, now with the current), dispel and beat, centrifugal 5 minutes of 1000rpm, discard supernatant, add fresh stationary liquid, dispel, effect 20-30 minute, centrifugal 5 minutes of 1000rpm, abandons supernatant again, adds 0.5mL stationary liquid, makes cell suspension;
6) cell suspension is dripped at 40cm place above slide glass slide (bubble in 30% ethanol, 4 DEG C of refrigerator precoolings), dispels immediately, and spirit lamp is dried;
7) Gimsa stoste: 1 × PBS=1:9 dyeing 20 minutes, tap water rinses.Result as shown in Figure 6.
Analysis chart 5 and 6.This result for random select to have calculated after 100 finely dispersed karyomit(e)s add up gained with SSCP.The chromosome abnormalty of CTSC-1 clone, the karyomit(e) of CTSC-1 all has distribution from 47 to 80, from 45 to 80 7 of settings intervals, the interval cell of result demonstration 60-64 and 65-69 is maximum, is similar to triploid.G band results of karyotype, at Microscopic observation, shows that different cell chromosomes is substantially all aneuploids, just number difference, and chromosomal exchange situation is all different, cannot add up unified karyomit(e) exchange situation.This result has also shown the chromosome instability of tumour cell.
The biological characteristics of 6.2CTSC-1 cell
6.2.2.1 cell counting detects CAL27 cell, the cell growth curve of CTSC-1 cell and doubling time.
1) the CAL27 cell of taking the logarithm vegetative period, CTSC-1 cell, is inoculated in 24 orifice plates with the cell concn in 3000/ml/ hole;
2) every 24h counts once, carries out cell counting after 1% trysinization, continuous counter 6 days;
3) taking every day cell density average as ordinate zou, incubation time is X-coordinate, draw cell growth curve.Result as shown in Figure 7.
4) calculate the doubling time by following formula.
TD=t log2/（logNt-logN0）
(TD: doubling time; T: incubation time: Nt: cultivate the cell count after t hour; N0: postvaccinal cell count)
Analysis chart 7, this experiment is taking CAL27 cell as contrast, detect the growth curve of CTSC-1 cell in the 10th generation and the 30th generation, under the culture condition of DF+5%FBS, the doubling time of CTSC-1 cell is 37.52 ± 1.34 hours and 30.85 ± 0.53 hours, aspect multiplication capacity, short algebraically continues cultured cells system and does not significantly change.Control cells is that the doubling time of CAL27 is 18.11 ± 0.29 hours, and by contrast, CTSC-1 cell proliferation speed is slower, because CAL27 clone incubation time is longer, affected by environment larger, and the CTSC-1 cell cultures time is short, may be closer to tumour upgrowth situation in vivo.
6.2.2.2, clone forms in BME
1) BME is placed on ice, puts into 4 DEG C of refrigerator overnight and dissolve;
2) digestion logarithmic phase CTSC-1 cell, counting, a small amount of DF is resuspended;
3) the CTSC-1 cell of some amount is added in BME, notice that whole process all will be on ice, when piping and druming mixes, avoid producing bubble;
4) plant in a hole of 96 orifice plates, after solidifying, upper strata adds 100 μ lDF+10%FBS nutrient solutions;
5) within 3 days, change a not good liquor, Continuous Observation two weeks.
BME clone forms result as shown in Figure 8, is having matrix to exist, and in the situation of DF+10%FBS culture condition, CTSC-1 cell can form approximately 40 μ m clones, and rate of formation is 1.46 ± 0.15%.
6.2.2.3CTSC-1 the tumorigenicity of cell
In BALb/c nude mouse, become knurl experiment
1) the adherent CTSC-1 cell of digestion in logarithmic phase, is resuspended in 1 × PBS;
2) be subcutaneously injected into the back, both sides of female BalB/C nude mice of 6-8 week, be divided into 1 × 10
7, 2 × 10
6two order of magnitude groups;
43) observe once weekly, measure size, after 3 months, put to death and take pictures.
Above experimentation on animals meets the requirement of Declaration of Helsinki (The Declaration of Helsinki), and obtains the approval of Ethics Committee of Zhongshan University and the accreditation of Experimental Animal Center.
Inject altogether 4 nude mices, every kind of clone is injected two, an injection 1 × 10
7individual cell/100 microlitre, another injection 2 × 10
6individual cell/100 microlitre.Tumorigenesis mouse starts Continuous Observation growing state from cell injection, measures diameter of tumor, takes pictures, puts to death nude mice, tumour is separated after 3 months.
1 × 10
7the nude mice of CTSC-1 cell injection can form tumour and not find macroscopic metastasis, do not invade.The inclined to one side canescence of tumour color, surface is covered with blood vessel, is bean curd slag specimen after incision.
As shown in Figure 9, the tumor biopsy H & E demonstration of dyeing, tumour is squamous cell cancer, can observe keratin pearl.Get part cell cultures, observe with epithelioid cell's form was consistent originally, can stablize propagation, frozen for subsequent use after amplification.
Two, enrichment and the CHARACTERISTICS IDENTIFICATION of tumor stem cell in tongue squamous cell cancer cell
1 material explanation
Clone and tissue mainly contain CTSC-1 clone and cell derived patient's tissue slice, and CTSC-1 clone is cultivated gained voluntarily by this laboratory, organizes and all takes from Zhongshan University's attached brilliance stomatological hospital excision sample.
2 key instruments
| Instrument title | Producer | Instrument title | Producer |
| Laser co-focusing | Leica | Magnetic stirring apparatus | IKA |
| Transmission electron microscope | NEC JEM | Quantitative PCR instrument | Roche LightCycler480 |
| Microplate reader | Bio-ted | Ultracentrifuge | BeckMan |
| Albumen bilateral system | GE | The same chapter 2 of all the other instruments |
3 main agents
| BSA | Sigma | Urea | GE |
| FGF2 | Peprotech | CHAPS | GE |
| TGFβ | Peprotech | IPG damping fluid | GE |
| ployHEMA | Sigma | Poly-lysine | Foochow steps new |
| DAB working fluid | DAKO | Hoechst33342 | Sigma |
| Fat induced liquid | GIBCO | Verapamil | Sigma |
| Fat stains liquid (oil red staining fluid) | Xiamen steps prestige | CCK8 | Dojindo |
| Primary antibodie antibody diluent | CST | DAPI | DAKO |
| Lowlenthal serum | Foochow steps new | Anti-cancellation mountant | DAKO |
All the other reagent are same, foundation and the CHARACTERISTICS IDENTIFICATION of tongue squamous cell cancer clone CTSC-1
4 main solution and formulas
4.1 cell cultures
1) 0.7% agarose (agarose): 0.7g agarose adds 100ml ultrapure water, uses after autoclave sterilization.
2) serum-free tumor stem cell is cultivated the factor (8F): patent is maintained secrecy.
3) Trypsin inhibitor (TI): take 1.25g trypsin inhibitor and be dissolved in 1 × PBS of 250ml, be made into 10 × TI ,-20 DEG C of preservations.Before using, be diluted to 1 × TI with 1 × PBS buffer and stop peptic cell.
4) Poly-2-hydroxyethyl methacrylate (polyHEMA): 95% alcohol is made into 36mg/mL, 4 DEG C of refrigerator overnight are dissolved, very thickness.
Other solution is same, foundation and the CHARACTERISTICS IDENTIFICATION of tongue squamous cell cancer clone CTSC-1.
4.2 histogenic immunity chemistry
1) 3% H
2o
2the H of/methanol solution: 20ml30%
2o
2with 180ml methyl alcohol
2) citrate buffer solution: 0.01M, contains trisodium citrate 3g, citric acid 0.4g, 1L secondary water in pH6.0:1L
5 antibody
6 primers
Nanog Forward：CAAAGGCAAACAACCCACTT
Reverse：TCTGCTGGAGGCTGAGGTAT
Oct4 Forward：CGACCATCTGCCGCTTTGAG
Reverse：CCCCCTGTCCCCCATTCCTA
Sox2 Forward：ATGCACCGCTACGACGTGA
Reverse：CTTTTGCACCCCTCCCATTT
c-kit Forward：ATGTGGGCAAGACTTCTGCCTA
Reverse：ATCATGCCAGCTACGATTA
ABCA1 Forward：TCTGGAAAGCTCTGAAGCCG
Reverse：TGAGTTCCTCCCACATGCCT
ABCB1 Forward：CCCATCATTGCAATAGCAGG
Reverse：GTTCAAACTTCTGCTCCTGA
ABCC1 Forward：CTTCTGGAGGAATTGGTTGTATAGAAG
Reverse：GGTAGACCCAGACAAGGATGTTAGA
ABCG1 Forward：ACCGGGGAAAAGTCTGCAAT
Reverse：TCACCAGCCGACTGTTCTGA
ABCG2 Forward：AGTTCCATGGCACTGGCCATA
Reverse：TCAGGTAGGCAATTGTGAGG
7, method and result
7.1CTSC-1 there is parts of fine cellular expression stem cell molecular marked compound in clone
7.1.1RT-PCR reverse transcription method detects the Sox2 in CTSC-1 cell, Nanog, the expression of the mRNA of Oct4
Adopt the method identical with 6.1.4.1 to extract total RNA of CTSC-1 cell, and employing and the 6.1.4.1.3 reverse transcription method cDNA that is CTSC-1 cell by total RNA reverse transcription of CTSC-1 cell.Detect the Sox2 in CTSC-1 cell, Nanog, the expression of the mRNA of Oct4, result shows CTSC-1 cell expressing Sox2, Nanog, the mRNA of Oct4.Subsequently, also confirmed that with the expression that Western immunoblotting has detected Sox2 its protein level is consistent with mrna expression level.
7.1.2 cell immunofluorescent staining method detects CTSC-1 clone to CD133, Sox2, Nanog, Oct4, SSEA-1, SSEA-4, TRA-1-60, the expression of TRA-1-81
Cell immunofluorescent staining method is as follows:
1) by clean aseptic cover glass in the each hole as for six orifice plates, the coated slide of I type mouse tail collagen more than 1 hour, is drawn supernatant, and 1 × PBS washes 2 times, stand-by;
2) the CTSC-1 cell of digestion logarithmic phase, resuspended rear kind enters to have in six orifice plates of cover glass;
3) be placed in CO2gas incubator and be cultured to the about 70%-80% of cell density;
4) 1 × PBS washes slide 2 times, fixes 10 minutes by the 4%PFA room temperature of precooling;
5) abandon stationary liquid, 1 × PBS washes 3 times, 10 minutes/time;
6) drip containing 1 × PBS of 5%BSA and mix (1:1) with lowlenthal serum confining liquid, seal 1 hour;
7) inhale and abandon confining liquid, drip the suitably primary antibodie of dilution, 4 DEG C of refrigerator overnight;
8) inhale and abandon primary antibodie, 1 × PBS washes 3 times, 10 minutes/time;
9) drip fluorescein-labelled two of suitable same kind of diluting and resist, incubated at room 1-2 hour;
10) inhale and abandon two anti-ly, 1 × PBS washes 3 times, 10 minutes/time;
11) with the mountant mounting containing DAPI;
12) under laser confocal microscope, observe, choose at random 3 visuals field (10 × 10 times) and take pictures and add up, the result of taking pictures is as Figure 10, and statistical result showed is at table 2.
Table 2 immunofluorescence detects the statistics of cell expressing stem cell markers
| % | CD133 | Sox2 | Nanog | Oct4 | SSEA-1 | SSEA-4 | TRA-1-60 | TRA-1-81 |
| CTSC-1 | 99.0±0.8 | 63.8±1.8 | <1 | 36.3±2.6 | 7.3±1.5 | 40.2±1.2 | 4.36±1.0 | 37.3±1.2 |
The result of above-mentioned experiment has all been pointed out and in cell, has been had tumor stem cell, but results suggest CD133 all cells in CTSC-1 clone is all expressed, therefore be not suitable in this experiment the screening of the marker for doing tongue cancer stem cell, remaining stem cell marker only has part cell to present positive expression.
Tumor stem cell in 7.2 serum-free suspension culture enrichment CTSC-1 clones
The CTSC-1 attached cell of digestion logarithmic phase, counting, is resuspended in DF+8F nutrient solution; Plant to enter to use in advance in the coated culture dish of aseptic 0.7%agarose.Found that, in the coated ware of agarose, by after serum-free for attached cell (DF+8F) nutrient solution suspension culture, can observe sacculus fine and close, neat in edge and form, result is as Figure 13.Then, we determine the optimum cell thickness of sowing of enrichment tumor stem cell, observe 1 × 10
5, 5 × 10
5, 1 × 10
6, 2 × 10
6, 5 × 10
6the impact of five cell count magnitudes of/10cm on bioaccumulation efficiency.Found that 2 × 10
6under the quantity of/10cm, without adding the somatomedin such as FGF2 or TGF-β, the plastidogenetic Balloon size of CTSC-1 is more even, and edge is more neat, cell state is good, therefore the condition unification of follow-up cultivation sacculus is: DF+8F, 0.7%agarose are coated with 10cm ware, 2X10
6individual cell/ware, the culture condition while going down to posterity is also like this.
As shown in figure 11, light Microscopic observation, balloon structure is compacted, and entirety is bright, in sacculus, can not clearly distinguish cell and iuntercellular boundary.In the same time of cultivating, size the heterogeneity of sacculus, more than large diameter can reach 100 μ m, little diameter only has 30 μ m left and right.As shown in figure 12, H & E dyeing sacculus shows spheroid densification.After counting, plant lower 2 × 10
6individual cell, sacculus formed rear cultivation after 7 days, calculated sacculus more than 50 μ m under light microscopic, and result shows that CTSC-1 cell can form approximately 2000 cells, is about 0.10 ± 0.05% of kind of lower cell count.
Figure 13 demonstration, sacculus cell and attached cell do not have notable difference to the expression level of CK8, CK18, CK19, and prompting tumor stem cell does not obviously change on cell type.
The biological characteristics of 7.3CTSC-1 sacculus
By the experimental result of this research, and in conjunction with bibliographical information, think DF+10%FBS cultivate attached cell in contain a small amount of tumor stem cell, and in the sacculus cell of DF+8F suspension culture, contain more tumor stem cell, therefore, the experiment of this research, using attached cell as reference, is carried out a series of analysis and research to tumor stem cell.
7.3.1CTSC-1 the comparative analysis of the cell cycle of sacculus cell and attached cell
Utilize the cell cycle that flow cytometer carries out to detect, cell is divided into 3 classes, the first kind is the cell in the G0/G1 phase, and the cell of G0 phase stops division, and the cell of G1 phase is just being prepared division; Equations of The Second Kind is the cell of S phase, and the cell of this period is carrying out chromosomal copying; The 3rd class is the G2/M phase, and the cell of this period has completed chromosomal doubling.The CTSC-1 attached cell G0/G1 phase is that 72.39 ± 0.87%, the CTSC-1 sacculus cell G0/G1 phase is 88.7 ± 1.95%, and both compare, and has more cell in the G0/G1 phase in sacculus, and difference has statistical significance (P < 0.05).The Leukopenia explanation of division, the culture condition of suspension serum-free, can make tumor stem cell well maintain dryness.
7.3.2CTSC-1 the contrast of the clonality of sacculus cell and attached cell
Attached cell and sacculus cell are digested respectively for unicellular, unicellular kind is entered in BME, with the culture condition of DF+8F, observe the situation that clone forms in BME.And clone's formation result is added up, as shown in figure 14.
7.3.3CTSC-1 the contrast of the resistance of sacculus cell and attached cell
This experiment utilizes the method for CCK8 to detect CTSC-1 sacculus and the tolerance of attached cell to 5-Fu and two kinds of anticarcinogens of DDP.Experiment is divided into 5-Fu and two experimental group of DDP, in 5-Fu group, in the time of the concentration of 100 μ g/mL, is 47.5% to CTSC-1 attached cell cell lethality, is 21.4% to CTSC-1 sacculus cell lethality.In DDP group, CTSC-1 attached cell median lethal concentration is 10 μ g/mL, and CTSC-1 sacculus cell median lethal concentration is 30 μ g/mL, and the tolerance difference of chemotherapeutics is had to statistical significance (P<0.01).Result shows the rising along with chemotherapeutics concentration, and cell survival rate all reduces, but under same drug level effect, the survival rate of sacculus is higher than attached cell.Proving that in sacculus, mdr cell content is higher, may be because the high institute of tumor stem cell content causes.By detecting the several main genes relevant to resistance of ABC family, as ABCA1, ABCB1, ABCC1, ABCG1, ABCG2, expression after find, the ABCG1 of sacculus is than the up-regulated of adherent cell, prompting may be relevant to ABCG1 path.
7.3.5CTSC-1 the contrast that the stem cell molecular marker of sacculus cell and attached cell is expressed
The expression of the significant molecule protein of this research application flow cytometer detection stem cell, as shown in figure 15, the demonstration of flow cytometer detected result, the expression of CTSC-1 sacculus cell Sox2 raises than CTSC-1 cell expressing.And the expression of SSEA-1 is CTSC-1 attached cell 20.16% positive, and CTSC-1 sacculus is 56.35% positive; CTSC-1 sacculus cell is compared up-regulated with attached cell, and difference has statistical significance.Many than in attached cell of the cell of high expression level Sox2 and SSEA-1 in results suggest sacculus cell.
7.3.6CTSC-1 sacculus has certain differentiation potential
Having differentiation potential is a large feature for stem cell, so this experiment has detected the differentiation potential of CTSC-1 sacculus cell by two kinds of methods, and contrasts with CTSC-1 attached cell.First method is, sacculus kind in culture dish that can be adherent, add DF+10%FBS nutrient solution, continue to cultivate, observe that sacculus can differentiate gradually and the original similar epithelial cell of attached cell, at the 2nd day that cultivates, only the have an appointment cytodifferentiation of 10%-20% of CTSC-1 became squamous cell, after cultivating 7-10 days, CTSC-1 sacculus is just all divided into squamous cell.
Second method is the method by above-mentioned fatty inducing culture, detects the differentiation capability of CTSC-1 sacculus cell, and CTSC-1 attached cell is as contrast, and inducing culture carries out fat stains after 30 days, and result as shown in figure 16.Attached cell does not have obvious form to change, more but cavity appears in tenuigenin.CTSC-1 sacculus is after induction, in the middle of spheroid, a part of cell is significantly cellular, the cell at these structure places is round, less, tenuigenin is obviously with particle, and these particles can be dyed orange by fat stains liquid, the peripheral free cell breaking up away of spheroid presents Epithelial, and attached cell is similar and the tenuigenin of cell does not have obvious particle.The closer to the cell of polynuclear plane, the particle in tenuigenin is more obvious, and there is a certain amount of tumor stem cell the inside of prompting CTSC-1 sacculus becomes certain spread pattern.
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, its framework form can be flexible and changeable, can subseries product.Just make some simple deduction or replace, all should be considered as belonging to the present invention by the definite scope of patent protection of submitted to claims.
Claims (5)
1. the establishment method of Chinese's tongue squamous cell cancer clone CTSC-1, is characterized in that, comprises following concrete steps:
A) adopt tissue block adherent method to carry out the former culture of tongue squamous cell cancer cell;
B) cultivation of going down to posterity in the time that cell density reaches approximately 80%;
C) the stable cell that goes down to posterity is detected and shows cell expressing people tongue squamous cell cancer cell sign molecule CK8,18,19 through RT-PCR;
D) detect attached cell through immunoblot experiment and express people's tongue squamous cell cancer cell sign molecule CK8,18 albumen, prove successfully to set up Chinese's tongue squamous cell cancer clone CTSC-1 from molecular level thus.
2. the establishment method of Chinese's tongue squamous cell cancer clone CTSC-1 as claimed in claim 1, is characterized in that, the concrete grammar of steps A is:
1) the coated culture dish room temperature of type i collagen is static more than 1 hour, and 1 × PBS washes ware once, stand-by;
2) prepare nutrient solution, be put in 37 DEG C of thermostat water baths incubation 10 minutes;
3) in super clean bench, take out tongue squamous cell cancer tissue, in alcohol, sterilization is no more than 10 seconds, soaks in 1 × PBS, removes unwanted position, is put in nutrient solution;
4) tissue is cut into fine grained chippings, evenly divides and plant in culture dish, add appropriate nutrient solution, make to organize half to be dipped in nutrient solution;
5) be placed in 37 DEG C, 5%CO
2incubator in cultivate;
6) within second day, supplement appropriate nutrient solution to submergence tissue block slightly;
7) visual cell's growing state suitably changes liquid.
3. the establishment method of Chinese's tongue squamous cell cancer clone CTSC-1 as claimed in claim 1, is characterized in that, the concrete grammar of step B is:
1) abandon nutrient solution, wash once with 1 × PBS, add tryptic digestion;
2) add serum to stop digestion;
3) piping and druming cell, is placed in centrifuge tube, adds appropriate nutrient solution piping and druming;
4) centrifugal 1000rpm, 5 minutes;
5) abandon supernatant, add appropriate nutrient solution piping and druming loose;
6) cell suspension is added in new culture dish, obtain described Chinese's tongue squamous cell cancer clone CTSC-1.
4. the purposes of Chinese's tongue squamous cell cancer clone CTSC-1 as claimed in claim 1 in the medicine of research treatment people tongue squamous cell cancer.
5. the purposes of Chinese's tongue squamous cell cancer clone CTSC-1 as claimed in claim 1 in the medicine for the treatment of people tongue squamous cell cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374517.2A CN103966169A (en) | 2012-08-24 | 2013-08-23 | Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210306873.6 | 2012-08-24 | ||
| CN 201210306873 CN102911915A (en) | 2012-08-24 | 2012-08-24 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
| CN201310374517.2A CN103966169A (en) | 2012-08-24 | 2013-08-23 | Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103966169A true CN103966169A (en) | 2014-08-06 |
Family
ID=47610496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210306873 Pending CN102911915A (en) | 2012-08-24 | 2012-08-24 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
| CN201310374517.2A Pending CN103966169A (en) | 2012-08-24 | 2013-08-23 | Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210306873 Pending CN102911915A (en) | 2012-08-24 | 2012-08-24 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102911915A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493769A (en) * | 2021-06-15 | 2021-10-12 | 武汉大学 | Human tongue squamous carcinoma cell line and application thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102911915A (en) * | 2012-08-24 | 2013-02-06 | 中山大学 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
| CN105462928B (en) * | 2015-10-30 | 2019-04-02 | 中山大学 | A kind of Chinese oral cavity K-1735 COMM-1 and its method for building up |
| CN108841959B (en) * | 2018-07-12 | 2022-03-01 | 吉林大学 | Kit and system for predicting susceptibility of oral cavity and head and neck malignant tumors |
| CN110643571B (en) * | 2019-10-22 | 2021-07-27 | 康妍葆(北京)干细胞科技有限公司 | Application of human keratin 6A in stem cell culture and product |
| CN118064369A (en) * | 2024-02-18 | 2024-05-24 | 首都医科大学附属北京天坛医院 | Human brain glioma cell line, and progeny cell line and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861786A (en) * | 2005-05-11 | 2006-11-15 | 郭伟 | Establishing and application of scale cancer cell line of purify species New Zealand mice oral cavaty and palatal surface parts |
| CN102002477A (en) * | 2010-12-01 | 2011-04-06 | 四川大学 | Method for culturing and amplifying odontogenic epithelial cells |
| CN102911915A (en) * | 2012-08-24 | 2013-02-06 | 中山大学 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
-
2012
- 2012-08-24 CN CN 201210306873 patent/CN102911915A/en active Pending
-
2013
- 2013-08-23 CN CN201310374517.2A patent/CN103966169A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861786A (en) * | 2005-05-11 | 2006-11-15 | 郭伟 | Establishing and application of scale cancer cell line of purify species New Zealand mice oral cavaty and palatal surface parts |
| CN102002477A (en) * | 2010-12-01 | 2011-04-06 | 四川大学 | Method for culturing and amplifying odontogenic epithelial cells |
| CN102911915A (en) * | 2012-08-24 | 2013-02-06 | 中山大学 | Chinese tongue squamous cancer cell line (CTSC-1) and establishing method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 何荣根 等: "人舌鳞状细胞癌Tca8113细胞系的建立及其生物学特性", 《肿瘤》 * |
| 姜辉 等: "细胞角蛋白表达在诊断皮肤鳞状细胞癌和基底细胞癌中的应用", 《实验与检验医学》 * |
| 孙莉 等: "七种细胞角蛋白在皮肤上皮性肿瘤中的表达", 《中华皮肤科杂志》 * |
| 潘琼婧: "人的恶性肿瘤连续性细胞系(株)的建系(株)标准的建议", 《细胞生物学杂志》 * |
| 董海龙 等: "人子宫颈鳞状细胞癌细胞系HCC-0214的建立及其生物学特性", 《中华肿瘤杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493769A (en) * | 2021-06-15 | 2021-10-12 | 武汉大学 | Human tongue squamous carcinoma cell line and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102911915A (en) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103966169A (en) | Chinese people tongue squamous epithelial cell cancer cell line CTSC-1 and establishment method thereof | |
| CN109609460B (en) | A kind of human glioma cell line and its method for building up and application | |
| CN101855339A (en) | Human cancer stem cells | |
| CN104017868B (en) | SETD4 is the purposes in preparation treatment pancreatic cancer drug in the purposes prepared in diagnosis of pancreatic cancer and/or prognosis kit and SETD4 blocker | |
| CN102821600A (en) | Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein | |
| CN102168065A (en) | Method for inducing human umbilical cord mesenchymal stem cells in vitro into liver cells and application thereof | |
| CN111979290B (en) | Application of SPP1 gene in preparation of medicine for enhancing sensitivity of ovarian cancer patient to PARP inhibitor | |
| CN105102614A (en) | Method for obtaining cell mass containing cancer stem cell | |
| CN102690784B (en) | The foundation of hepatoma cell line HCC-LY10 and application | |
| TWI461535B (en) | Isolated human liver tumor cell line and method of agent screening | |
| CN103881975B (en) | Human Prostate Cancer Cells and primary separation and Culture thereof and Secondary Culture method and purposes | |
| CN104031884B (en) | The protein arginine transmethylase 7 application in cancer cell metastasis | |
| CN103849602A (en) | Bovine testicle cell line as well as establishment method and application thereof | |
| DeComas et al. | Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor | |
| CN103667441A (en) | Hsa-miR-145-5p kit and use of mature body analogy of Hsa-miR-145-5p | |
| CN105062975B (en) | The drug resistant gastrointestinal stromal tumor cell lines of Imatinib and Nude Mouse Model construction method | |
| CN104745530A (en) | Human hepatocellular carcinoma cell line, and establishing method and application thereof | |
| CN106479981B (en) | A kind of people's Endometrial carcinoma cell line and its method for building up | |
| CN103463619A (en) | Application of bone morphogenetic protein 4 in cancer inhibition | |
| CN102168085A (en) | SiRNA for inhibiting expression of miR-130b gene and expression vector and application of siRNA or/and expression vector to preparation of medicament for improving treatment effect of liver cancer | |
| CN103756966A (en) | Chinese tongue squamous epithelial cell carcinoma cell line CTSC-2 and establishment method thereof | |
| CN104531760B (en) | The short hairpin RNA interference plasmid and its application process of Dp71 albumen | |
| CN101928747B (en) | Application of E3 ubiquitin ligase CHIP in gliomatosis cerebri disease | |
| CN105695394A (en) | In vitro culture method of mouse salivary gland organ | |
| CN102690785A (en) | Establishment and application of hepatocellular carcinoma cell line HCC-LY5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140806 |